Significant impact of +105 A>C promoter polymorphism in IL-18 cytokine in patients with kidney stone disease

Mohammad A. Thoker, Arshad A. Pandith, Shahnawaz A. Sheikh, Aashaq Hussain, Mosin S. Khan, Faheem Shehjar, Zafar A. Shah, Mohammad Saleem Wani

Abstract


Background: Inflammation may be one cause of nephrolithiasis and the interleukin-18 (IL-18) encoding gene   polymorphisms at +105 A>C has been implicated in several inflammation related diseases. The aim of this study was to test whether IL-18+105 A>C polymorphisms could act as genetic marker for renal stone disease. A case-control study was conducted to observe the genotype distribution of IL-18+105 A>C, to elucidate the possible role of this SNP as risk factor in renal stone development and to examine its correlation with the clinico-pathologic variables.

Methods: Using the Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP) technique, we tested the genotype distribution of 160 nephrolithiasis patients in comparison with 200 disease free controls from the same geographical region.  

Results: We observed significant differences of IL-18+105 A to C between the controls and patients with odds ratio 5.4 (P = 0.001). The prevalence of the variant genotypes AC + CC in the patients was higher than that in the controls (45% v/s 30%) and showed a significant association (P = 0.003). Moreover, the frequency per copy of the C allele of IL-18+105 A>C was found to be implicated more in patient group 0.27 as against only 0.16 in controls (P = 0.0003). Further, males and subjects with <45 years of age in patient group were significantly associated with variant genotype (P <0.05).

Conclusion: Thus, it is evident from our study that IL-18+105 A>C is implicated in renal stone disease, and that the rare, C related allele is connected with higher susceptibility to nephrolithiasis.

 


Keywords


Genetic markers, Inflammation, Nephrolithiasis, Gene polymorphisms, IL-18+105 A>C

Full Text:

PDF

References


Stamatelou KK, Francis ME, Jones CA, Nyberg LM, Curhan GC. Time trends in reported prevalence of kidney stones in the United States: 1976-1994. Kidney Int. 2003;63:1817-23.

West B, Luke A, Durazo-Arvizu RA, Cao G, Shoham D, Kramer H. Metabolic syndrome and self-reported history of kidney stones: the National Health and Nutrition Examination Survey (NHANES III) 1988-1994. Am J Kidney Dis. 2008;51:741-7.

Rivers K, Shetty S, Menon M. When and how to evaluate a patient with nephrolithiasis. Urol Clin North Am. 2000;27:203-13.

Polito C, La Manna A, Nappi B, Villani J, Di Toro R. Idiopathic hypercalciuria and hyperuricosuria: family prevalence of nephrolithiasis. Pediatr Nephrol. 2000;14:1102-4.

Edvardsson VO, Palsson R, Indridason OS, Thorvaldsson S, Stefansson K. Familiality of kidney stone disease in Iceland. Scand J Urol Nephrol. 2009;43:1-5.

Rendina D, Mossetti G, Viceconti R, Sorrentino M, Castaldo R, Manno G, et al. Association between vitamin D receptor gene polymorphisms and fasting idiopathic hypercalciuria in recurrent stoneforming patients. Urology. 2004;4:833-8.

Khan SR, Kok DJ. Modulators of urinary stone formation. Front Biosci. 2004;9:1450-82.

Khan SR. Role of renal epithelial cells in the initiation of calcium oxalate stones. Nephron Exp Nephrol. 2004;98:55-60.

Jonassen JA, Kohjimoto Y, Scheid CR, Schmidt M. Oxalate toxicity in renal cells. Urol Res. 2005;33:329-39.

Schepers MS, van Ballegooijen ES, Bangma CH, Verkoelen CF. Oxalate is toxic to renal tubular cells only at supraphysiologic concentrations. Kidney Int. 2005;68:1660-9.

Chen WC, Wu HC, Chen HY, Wu MC, Hsu CD, Tsai FJ. Interleukin-1beta gene and receptor antagonist gene polymorphisms in patients with calcium oxalate stones. Urol Res. 2001;29:321-4.

Dinarello CA. Interleukin-18 and the pathogenesis of inflammatory diseases. Semin Nephrol. 2007;27:98-114.

Striz I, Krasna E, Honsova E, Lacha J, Petrickova K, Jaresova M, et al. Interleukin 18 (IL-18) upregulation in acute rejection of kidney allograft. Immunol Lett. 2005;99:30-5.

Devarajan P. Emerging biomarkers of acute kidney injury. Contrib Nephrol. 2007;156:203-12.

Gauer S, Sichler O, Obermuller N, Holzmann Y, Kiss E, Sobkowiak E, et al. IL-18 is expressed in the intercalated cell of human kidney. Kidney Int. 2007;72:1081-7.

Kretowski A, Mironczuk K, Karpinska A, Bojaryn U, Kinalski M, Puchalski Z, et al. Interleukin-18 promoter polymorphisms in type 1 diabetes. Diabetes. 2002;51:3347-9.

Lee CC, Lin WY, Wan L, Tsai Y, Lin YJ, Tsai CH, et al. Interleukin-18 gene polymorphism, but not interleukin-2 gene polymorphism, is associated with rheumatoid arthritis. Immunogenetics. 2007;59:433-9.

Chen WC, Wu HC, Chen HY, Wu MC, Hsu CD, Tsai FJ. Interleukin-1beta gene and receptor antagonist gene polymorphisms in patients with calcium oxalate stones. Urol Res. 2001;29:321-4.

Goodman HO, Holmes RP, Assimos DG. Genetic factors in calcium oxalate stone disease. J Urol. 1995;153:301-7.

Costa S, Pinto D, Pereira D, Rodrigues H, Cameselle-Teijeiro J, Medeiros R, et al. Importance of TP53 codon 72 and intron 3 duplication 16 bp polymorphisms in prediction of susceptibility on breast cancer. BMC Cancer. 2008;8:32.

Dong GP, Yu ZS, Liang L, Zou CC, Fu JF, Wang CL. IL-18 gene promoter –137 C/G and –607 C/A polymorphisms in Chinese Han children with type 1 diabetes mellitus. Int J Immunogenet. 2007;34:75-9.

Kretowski A, Mironczuk K, Karpinska A, Bojaryn U, Kinalski M, Puchalski Z, et al. Interleukin-18 promoter polymorphisms in type 1 diabetes. Diabetes. 2002;51:3347-9.

Lee CC, Lin WY, Wan L, Tsai Y, Lin YJ, Tsai CH, et al. Interleukin-18 gene polymorphism, but not interleukin-2 gene polymorphism, is associated with rheumatoid arthritis. Immunogenetics. 2007;59:433-9.

Lai KC, Lin WY, Man KM, Tsai CH, Chen HY, Tsai FJ, et al. Association of interleukin-18 gene polymorphisms with calcium oxalate kidney stone disease. Scand J Urol Nephrol. 2010;44:20-6.

Striz I, Krasna E, Honsova E, Lacha J, Petrickova K, Jaresova M, et al. Interleukin 18 (IL-18) upregulation in acute rejection of kidney allograft. Immunol Lett. 2005;99:30-5.

Devarajan P. Emerging biomarkers of acute kidney injury. Contrib Nephrol. 2007;156:203-12.

Gauer S, Sichler O, Obermuller N, , Holzmann Y, Kiss E, Sobkowiak E, et al. IL-18 is expressed in the intercalated cell of human kidney. Kidney Int. 2007;72:1081-7.

Heilberg IP, Teixeira SH, Martini LA, Boim MA. Vitamin D receptor gene polymorphism and bone mineral density in hypercalciuric calcium-stone-forming patients. Nephron. 2002;90:51-7.

Nishijima S, Sugaya K, Naito A, Morozumi M, Hatano T, Ogawa Y. Association of vitamin D receptor gene polymorphism with urolithiasis. J Urol. 2002;167:2188-91.

Mittal RD, Bid HK, Kumar A, Bhandari M. Association of urokinase gene 3́-UTR polymorphism with calcium oxalate nephrolithiasis. J Endourol. 2006;20:157-60.